19 May 2020
Remote symptom monitoring using wearable technology: the relationship between mood, cognition and physical activity in depression
Capturing daily fluctuations in mood and cognition can help to more accurately monitor treatment response - but is this feasible for patients with depression?
In research presented at CNS2020, we examined the feasibility of high-frequency cognitive assessments, and their relationship with daily measures of depressive symptoms and physical activity.
21 April 2020
Examination of the neural basis of psychotic-like experiences in adolescence during processing of emotional faces
We caught up with Dr Evan Papanastasiou from King's College London to find out why he chose CANTAB to examine the neural basis of psychotic-like experiences in adolescence during processing of emotional faces.
30 March 2020
The FDA have released guidance urging clinical trials to go virtual where possible in response to the COVID-19 pandemic – so what are the best methods for ensuring patient safety and trial integrity during this transition? In this article, we will discuss some of the important aspects to consider when taking a therapeutic trial from the clinic to the patient’s home.
The full FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Pandemic is available here.
25 March 2020
Despite chemotherapy-associated cognitive impairment (CACI, aka chemobrain) affecting 75% of all cancer survivors, little is understood about the mechanisms underlying the disorder. In efforts to address this research gap, Prof Alexandre Chan from the University of California, Irvine used CANTAB to conduct an evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment. Read on to find out the results.
19 March 2020
We caught up with Lydia Devenney from Letterkenny Institute of Technology to find out why she chose CANTAB to assist her research into investigating attention, memory functioning, and mood in a natural setting with real‐life alcohol consumption levels.
28 February 2020
Cambridge Cognition's Jemma Clark shares her insight into how cognitive function can be affected in certain rare diseases and why it is important to include cognitive tests in rare disease trials.